1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for individuals in Fife Lake who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some centers and doctors are authorized to dispense specific meds to opioid dependent clients, many that are opioid-based themselves and are habit forming. In low enough doses however, the user does not experience being high and also doesn't experience acute cravings and is not in opioid withdrawal. Methadone is the first drug tried for this sole purpose, but there are alternative options to choose from.
Methadone is an opioid and is meant to be taken at an outpatient medical center certified to administer the med, which is taken daily in liquid or pill form. The price of the med is approximately $150 monthly. Buprenorphine is also an opiate based drug, and is in pill form often taken every other day. But unlike Methadone that is only be administered in highly structured clinics, Buprenorphine can be prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately just under $300 monthly for the generic version of the medication. There is also a version of buprenorphine containing the drug naloxone, that is a med that reverses the effects of opiates. An individual consuming this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken daily, and costs approximately $450 monthly. Naltrexone is another drug taken in opioid maintenance therapy, but unlike the other medications mentioned here it's an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 /month.
For All Drug and Alcohol Treatment Programs In Fife Lake, Click Here.
